Adocia | Cash Flow

Fiscal year is January-December. All values EUR Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
4,293.00
20,715.00
12,553.00
7,892.00
8,550.00
7,615
Depreciation, Depletion & Amortization
361.00
347.00
468.00
763.00
1,013.00
1,038
Other Funds
-
-
-
14.00
-
1,717
Funds from Operations
3,635.00
16,856.00
14,492.00
3,174.00
4,409.00
10,370
Changes in Working Capital
7,160.00
47,417.00
20,708.00
9,964.00
17,818.00
4,057
Net Operating Cash Flow
10,795.00
30,561.00
6,216.00
13,138.00
22,227.00
6,313
Capital Expenditures
428.00
401.00
1,284.00
8,079.00
1,980.00
Sale of Fixed Assets & Businesses
85.00
25.00
-
843.00
295.00
Purchase/Sale of Investments
400.00
202.00
20.00
47.00
-
Net Investing Cash Flow
57.00
174.00
804.00
7,189.00
1,685.00
Issuance/Reduction of Debt, Net
309.00
-
500.00
6,283.00
613.00
Net Financing Cash Flow
309.00
-
29,282.00
6,301.00
653.00
Net Change in Cash
11,047.00
30,387.00
22,262.00
14,026.00
23,259.00
Free Cash Flow
11,223.00
30,160.00
7,500.00
21,217.00
24,207.00
Other Sources
-
-
500.00
-
-
Change in Capital Stock
-
-
29,782.00
4.00
40.00

About Adocia

View Profile
Address
115 avenue Lacassagne
Lyon Rhone-Alpes 69003
France
Employees -
Website http://www.adocia.com
Updated 07/08/2019
Adocia SA is a clinical-stage biotechnology company, which engages in the development of medicines from already-approved therapeutic proteins and peptides. Its product pipelines include: BioChaperone Lispro; BioChaperone Combo; HinsBet; BioChaperone Human Glucagon; BioChaperone Glargine GLP-1; and BioChaperone Prandaial Combinations for T1D. The company was founded by Gérard, Olivier, and Rémi Soula on December 16, 2005 and is headquartered in Lyon, France.